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2. The relatives of all ca es of ickle-cell anaemia should
be tested for the sickle-cell phenomenon and, when it is
found, the significance of it should be explained. In par-
ticular the danger of marrying a near relative should be
stressed. Those found with the trait should be provided with
a wristband bearing the words 'sickle-cell trait".
3. A law prohibiting the marriage of closely related per-
sons might be introduced, or any such existing law might
be more strictly enforced.
SUM 1ARY
The commonly quoted racial incidence of sickle-cell anaemia
and sickle-cell trait does not apply in fatal. In Natal, both
occur more commonly in the Indian than in the Bantu ( egro)
population. The origin of the gene for this condition is dis-
cussed and it is concluded that it came, not from Africa as
might have been supposed. but from India. The difficulties of
recognizing the sickling phenomenon are tressed and methods
for overcoming them are suggested. Recommendations for the
prevention of sickle-cell anaemia are also discu sed.
We wish to thank the Medical Superintendent of King
Edward VBI Hospital. Durban, for permi ion 10 publi h
this paper, and Mrs F. Meer who commenled on certain social
aspects in the original draft.
ADDE DUM
Since this article was accepted for publication a further cases
of sickle-cell trait have been discovered in an Indian family
named James.
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LIVER-FUNCTION TESTS IN PRIMARY CANCER OF THE LIVER IN THE B TU*
I. BERSOHN, B.Sc., M.B., B.CH., F.C. PATH., L. R. PURVES, M.B., B.CH., M.MED. (PATH.), Sourh African /nsrilll/e
for Medical Research, A DE. W. GEDDES, M.B., CH.B.. Croll"n Mines Naril'e Hospiral, Johannesburg
The South African Primary Liver Cancer Research Group
was established in March 1965 for the purpose of investi-
gating all aspects of this disease in male Bantu mine-
workers, in whom it is a relatively common condition.'
The world distribution of this cancer is variable, being
uncommon in western countries, but common in Africa
south of the Sahara. In Africa it occurs not only in the
Bantu but in all people of Negro stock. It is 6 times
more common in Portuguese East Africans (88'3/100,000
per annum) than it is in South African Bantu
(14,8/100,000 per annum).' This contrasts with a lower
incidence (3'2/100,000 per annum) in the American
egro population.' The variable incidence suggests in-
creased susceptibility, or the possibility of environmental
aetiological factors.
A review of the literature on the value of liver-function
tests in the diagnosis of primary cancer of the liver re-
flects conflicting opinions, and it is generally stated that
most liver-function tests are of no value or of only
doubtful value.
The apparent fundamental difference in the develop-
ment of primary cancer of the liver in western and non-
western populations-e.g. the necessity for pre-existing
liver disease in the western populations-to a large de-
gree confuses the comparison of results from different
sources. Most detailed reports have come from western
communities.
Holley and Pierson' stated that damage must be ex-
tensive before any appreciable change could be detected
in liver-function tests in cases of primary liver cancer.
Spatt and Grayzel' stated that the most consistent ab-
normal liver-function tests in primary liver cancer were
a raised icteric index, a raised alkaline phosphatase level
and an abnormal bromsulphalein dye retention. The
serum protein, serum cholesterol and the cephalin floccu-
lation tests were not of use in diagnosis.
• Date received: 2 April 1969.
In Lichtman's opinion'; the bilirubin content wa
usually normal and the cephalin cholesterol test was
strongly positive in primary cancer of the liver and nega-
tive in secondary cancer. The thymol turbidity reaction
was more uniformly negative in hepatic cancer. The alka-
line phosphatase level might be normal in primary
cancers which develop in cirrhotic livers.
Spellberg' stated that Liver-function tests in primary
cancer of the liver were variable and depended on the
presence of underlying cirrhosi . If there was a marked
derangement of liver-function tests the presence of cir-
rhosis was likely. Two tests, however, were likely to be
disturbed in both primary and secondary malignant liver
disease, viz. the bromsulphalein dye-retention test and the
serum alkaline-phosphatase concentration.
Popper and Schaffner' stated that two findings were
suggestive of primary carcinoma, but their absence did
not exclude this diagnosis, viz. an elevation of serum
alkaline phosphata e out of proportion to the degree of
jaundice and an increase of erum mucoprotein to high
levels during the course of cirrhosis, since the levels were
low in uncomplicated cirrhosis, even with jaundice.
It has been shown' that the main diagnostic features in
differentiating malignant liver disease from cirrhosis of
the liver are a dissociation between tbe thymol turbidity
and flocculation te ts, a dissociation between the serum
bilirubin and alkaline phosphatase levels (especialJy a
raised alkaline phosphatase level in an anicteric patient),
a raised serum mucoprotein level, elevated alpha,- and
beta-globulin fractions and a high erum cholesterol level.
Lin Chao et al.w stated that, owing to the reserve power
and regenerative capacity of the liver, and to the fact
that the lesion in primary cancer of the liver was often
localized, liver-function tests were of little value in the
early diagno is of primary cancer of the liver. In view of
tbe high incidence of co-existent hepatic cirrho i and
primary hepatic cancer, positive results of liver-function
te ts obtained could have been due to cirrhosis rather
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than to cancer. In their opinion, increased activity of
serum alkaline phosphatase in the absence of jaundice
was of diagnostic value (in 130 cases, 54·6% exceeded 15
A units).
Saragoga et al." reported on the biochemistry of 7 cases
of primary carcinoma and regarded a high level of alka-
line phosphatase in the presence of low serum bilirubin
as an important diagnostic aid. This observation has also
been reported by others."'" These two tests and the con-
istently high level of the transaminases (SOOT / SOPT
ratio always greater than I) could be regarded as the bio-
chemical expression of Brem's concept of an 'expanding,
pace-occupying lesion'."
Kay,H in a review of 96 patients with primary hepatic
cancer, found that although the results of liver-function
tests were usually abnormal, they were not specific. In
the absence of non-hepatic disease the most specific test
was the serum alkaline phosphatase, especially if very
elevated.
Sherlock lS found the serum alkaline phosphatase, trans-
amina e, aJphaz-globulin, aldolase and bromsulphalein
dye retention to be increased in primary liver cancer.
Recently it has been shown that the presence of alpha-
feto-protein (AFP) is a reliable indicator of the presence
of primary cancer of the liver and that the proportion of
cases that show a positive result ranges from 50 to 79%.'9."
MATERlAL AND METHODS
JBeginning in March 1965, Bantu mineworkers of the
Witwatersrand and Orange Free State goldmines were
referred to the clinical unit at City Deep Mine Hospital,
Johannesburg, from other mine hospitals, for the investi-
gation of hepatomegaly suspected, on clinical grounds
only, of being due to primary liver cancer. Occasionally
cases were diagnosed incidentally at laparotomy, e.g. for
an 'acute abdomen'. Some cases resembled amoebic liver
disease and were initially misdiagnosed until biopsied and
perhaps even treated. Because these measures could possi-
bly vitiate the re ults of liver-function tests performed on
admission to the unit, these cases were excluded from
;this report.
Many patients arriving at the unit were clearly typical
cases of primary carcinoma of the liver-frank cancer
type I." After the diagnosis was made by histological
examination of a liver biopsy, patients were accepted for
tudy.
The first 200 consecutive patients with hepatomegaly
comprise the series that we are reporting.
There were 63 cases, negative for primary cancer of
·the liver by repeated biopsies. Liver-function tests were
not carried out in 2, leaving' 61 cases, designated as the
-<non-cancer' group. Since these cases were often lost to
follow-up and no final diagnosis could be made, the
possibility of some of these cases having primary liver
cancer could not be excluded. In fact, retrospective test-
ing of sera from these cases revealed a positive AFP test
:in 5 of these cases.
Primary extrahepatic malignancy was found in 6 cases;
~md in a further 6 cases the diagnosis remains in dispute
mstologically, but a positive AFP test was found in 5.
A definite histological diagnosis was made in 125 cases.
()f the 125 cases proved histologically, 17 were excluded
~n the grounds of having had previous treatment, biopsy
or laparotomy, and 15 were repatriated. In the remaining
93 patients the diagnosis was proved by postmortem
examination and it is these unequivocal cases which were
analysed further for this report. Subsequent analysis has,
however, revealed that, even if the biopsy-positive and
AFP-positive cases are included, the conclusions we reach
are the same.
Tables I and II depict the tribal composition and age
distribution of the cancer and non-cancer groups. The
provisional clinical diagnosis of the non-cancer group is
shown in Table Ill.
There was sufficient material to group 90 cases into
cirrhotic (48 cases) and non-cirrhotic categories (30 cases).
In 12 cases there was some doubt as to classification.
They had no naked-eye cirrhosis of the liver, and sections
taken at a distance from the tumour failed to show more
than a few foci of subcapsular nodular regeneration. A
cirrhotic liver was defined as one showing deformity of
the normal lobular architecture as the result of both
excessive fibrous tissue formation and nodular paren-
chymal hyperplasia or regeneration. This definition ex-
cluded hepatofibrosis and nodular regeneration without



















Nyasa (Malawi) I 6
Chewa (Malawi) I 0
Mlubali (Angola) I 0





There were no Transvaal Shangaans and no South African Basuto in the
~eries.
TABLE n. AGE DISTRlBUTION
Age
(years) Cancer Non-cancer
18 - 20 7 5
21 - 30 40 18
31 - 40 32 14
41 - 50 11 14
51 - 60 3 9
61 and over 0 1
Mean age 31·8 37-4
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Congestive cardiac failure 6
Amoebic hepatitis ...... 4
Tuberculosis (3 peritonitis) 4
Infective hepatitis 2





Ruptured rectus muscle. 1
Typhoid I
Total 61
fibrosis. True cirrhoses are generalized throughout the
liver." According to the above definition these 12 cases
should be grouped with the non-cirrhotic cases, but they
have been grouped separately for the purpose of this study.
Forty- even per cent of our cancer cases (if we include
cases with focal cirrhosis as non-cirrhotics) were there-
fore not associated with cirrhosis of the liver. These
figures are in contrast to those of Higginson,'" Thompson";
and Davies" who found that in their eries cancer of the
liver occurred in non-cirrhotic livers in 14°0. 21 0" and
11 0" of cases. Prates,' in 399 autopsy cases of liver cancer
in the Portuguese East African. showed that 87°0 were
associated with cirrhosis.
In the cancer group 41 U" had evidence of bilharziasi
on postmortem examination and 63°0 on clinical testing.
Tn the non-cancer group 53°" were positive for bilhar-
ziasis on clinical grounds.
Tn this series the ratio between Portugue e East Afri-
can and South African Bantu autopsies was 6·6 : I. This
was similar to the ratio obtained in autopsy material by
Berman.'~ who found that primary cancer of the liver
was almost 6 times more frequent in the Portuguese
East African than it was in the South African Bantu.
Rate studies in the Bantu population of Johannesburg
and in Lourens:o Marques have confirmed this increased
incidence.'.3
The biochemical tests carried out on the patients ad-
mitted to the study are listed in Table IV.
RES LTS
Tables VA- VD show the means. standard deviation and
statistical analyses of the cancer and non-cancer groups.
and cases with and without cirrhosis. Tables VIA-YID
show the percentage of abnormal results in the groups
studied. The 'Student' T test wa calculated by standard
methods with degrees of freedom equal to (total cases -2):
and the probability (p) of two sets of data. e.g. (A) and
(B + C). being significantly different. was obtained from
standard tables. For (e.g. 60 degrees of freedom) if the
result of 'Student's T' >2·39 then p<O'OI (highly signifi-
cant) and if 2·39 > 'Student's T results > 1·67 then
0·05 > p > 0'01 (possibly significant).
DISCUSSIO
The biochemical tests carried out in the pro ed cancer
group hawed in practically every instance marked devia-
tions from the normal range. This also applied to the
non-cancer group, but not to the same degree. There was.
however. in both groups a very wide scatter in most re-
sults which was reflected in the high standard deviations
(Tables VA-VD).
When the cancer and the non-cancer groups were com-
pared the striking feature was the marked elevation in
the enzyme levels in the cancer group. The SGOT.
SGOT jSGPT ratio. LDH. alpha-hydroxybutyric dehydro-
TABLE IV. BIOCHEMICAL TESTS CARRIED OUT
TeslS
Thymol turbidity (MacLagan)28
Thymol f1occulation ( eefe and Reinhold)'9
Colloidal red (Ducci)30 ..
Cephalin cholesterol f1occulation (Hanger)"
Takata Ara (UCkO)32 ..
Zinc ulphate turbidity (Kunkel)33 ..
Alkaline phosphatase (King and Armstrongp·
Bilirubin (Malloy and Evelyn)35
Pseudocholinesterase (M ichel)"6
Mucoprotein (atelson)37 ..
Cholesterol \S er and Webb38
Percentage esterified cholesterol J p ry
Glutamic oxaloacetic tran~aminase (SGOT) ~ Reitman and Frankel39
GlutamiC pyruvIc transaminase (SGPT) ~
Alpha-hydroxybutyric dehydrogena e (H BD) (Ellioll and Wilkinson)·o
Lactic dehydrogenase (LDH) (Wroblewski and LaDue)H
Lactic dehydrogenase isoenzyme fraction V (modified Raboo)·'
Aldolase (modified Boehringer kit) ..
Isocitric dehydrogenase (lCD) (Bowers)·3 ..
Leucine amino-peptidase (LAP) (Goldbarg and Rutenberg)H
Glutathione reductase (GR) (Kerppola, likkila and Pitkanen)'5






Gammaglobulin . . . . . .
(Electrophoresi wa carried out using the Beckman microzone apparatus.)







Up to 12·5 units
4-13 units
Upto 1·2mg. 100ml.
0-120 0 0 of norma I
activity
25-125 mg. 100 ml.
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Zinc sulphate turbidity (units)
HS p < ·01
PS 0·01 < p < 0·05
NS p "> 0·05
Proved Focal
cancer Non-cancer Cirrhosis No cirrhosis cirrhosis
(93 cases) 'p' (61 cases) (48 cases) 'p' (30 cases) (/2 cases)
5·6 ± 3·6 HS 3·9 ± 2·4 6·0 ± 3·4 NS 4·9 ± 3·7 5·0 ± 3·7
1·8 ± 1·8 NS 1·4 ± 1·6 2·1 ± 1·8 PS 1·4 ± 1·6 \·7 ± 1· 8
3·2 ± 1·4 NS 3·1 ± 1·4 3·6 ± 0·9 HS 2·8 ± \·7 2·7 ± 1·7
2·4 ± 1·8 S 3·9 ± 2·4 2·6 ± 1·7 PS 3·2 ± 1·8 2·5 ± 1·7
1·9 ± 1·0 S 1·7 ± 1·1 2·1 ± 1·0 PS 1·7 ± 1·0 1·6 ± 0·9
36·5 ± 16·2 PS 32·1 ± 12·1 40·6 ± 17·9 HS 30·7 ± 13·2 33·7 ± 1I·8
TABLE VB. MEANS, STANDARD DEVIATIONS AND STATISTICAL ANALYSES (ENZYMES)
Proved cancer Non-cancer Cirrhosis No cirrhosis Focal cirrhosis
(93 cases) 'p' (61 cases) (48 cases) 'p' (30 cases) (/2 cases)
Alkaline phosphatase (units) 27·8 ± 15·4 PS 20·9 ± 24·5 25·6 ± 14·7 NS 26·5 ± 12· 5 37·9 ± 20·2
SGOT (units) 195·5 ± 215·2 HS 77·5 ± 114·7 182·6 ± 153 ·1 NS 219·5 ± 315·4 177·2 ± 96·0
SGPT (units) 70·2 ± 93·7 NS 60·1 ± 99·3 53'7 ± 24·7 PS 103·9 ± 154·6 58·2 ± 39·6
SGOT/SGPT ratio 2·8 ± 1·8 HS 1·3 ± 0·7 3·3 ± 1·6 HS 2·1 ± 1·7 3·0 ± 1·2
LDH (units) 1,099'9 ± 1,043'4 HS 395·4 ± 207·4 1,100'3 ±1,140'7 NS 1,049' 0 ± 838·5 906·7 ± 449·9
HBD (units) 660·9 ± 715·9 HS 251 .3 ± 130· I 648·7 ± 733·3 NS 646·6 ± 572·7 500·0 ± 269·0
LDH/HBD ratio 1·7 ± 0·5 NS 1·6 ± 0·6 1·7 ± 0·4 NS 1·6 ± 0·3 1·8 ± 0'2
% LDH isoenzyme fraction V 28·6 ± 14·5 HS 16·5 ± 9·1 26·4 ± 14·4 NS 30·4 ± 14·3 31·2 ± 10'0
Aldolase (units) 61·4 ± 45· I HS 32·7 ± 13·7 55·7 ± 32·2 NS 52·0 ± 25·4 67·5 ± 25'9
ICD (units) 15·\ ± 9·6 HS 5·9 ± 3 ·1 13·9 ± 8·7 NS 16·2 ± 11·1 16·3 ± 10'2
LAP (units) 623·0 ± 431·3 HS 378·7 ± 226·4 484·4 ± 262·6 HS 763·3 ± 611·6 719·0 ± 292'4
5'nucleotidase (units) 30·7 ± 19·7 HS 19·0 ± 30·2 27·9 ± 19·4 NS 27·2 ± 15·9 46·9 ± 26'5
G R (units) 150·1 ± 92·8 HS 70·3 ± 38·2 135·0± 73·8 NS 150·9 ± 123·2 46·3 ± 63'7
Cholinesterase %ofnormal 50·3 ± 22·7 NS 55·8 ± 25·6 49·8 ± 23·8 NS 52·5 ± 23·5 44·5 ± 16'3
TABLE VC. MEANS, STA DARD DEVIATIONS A D STATISTICAL ANALYSES (PROTEINS)
Proved cancer Non-cancer Cirrhosis No cirrhosis Focal cirrhosis
(93 cases) 'p' (61 cases) (48 cases) 'p' (30 cases) (/2 cases)
Total protein (G/IOO mI.) 8·2 ± 0·9 NS 8·\ ± 0·8 8·2 ± 0·9 NS 8·0 ± 0·9 8·2 ± 0·8
Albumin % 39·5 ± 6·1 NS 41·3 ± 8·9 39·0 ± 6·1 NS 40·3 ± 6'4 38·6 ± 5 ·1
Albumin (G/IOO mI.) 3·2 ± 0·6 NS 3·3 ± 0·8 3·2 ± 0·6 NS 3·2 ± 0·6 3·1 ± 0·4
Alpha,-globulin % 6·0 ± 1·7 HS 4·8 ± 1·4 6·0 ± 1·6 NS 5·9 ± 1·5 6·4 ± 2·5
Alpha,-globulin (G/lOO mI.) 0'5 ± 0·1 HS 0·4 ± 0·1 0·5 ± 0·1 NS 0·5 ± 0·1 0·5 ± 0·2
Alpha 2-globulin % 9·8 ± 2·2 NS 9·8 ± 2·1 9·5 ± 1·9 PS 10·4 ± 2-4 9·9 ± 2·2
Alpha 2-globulin (G/I 00 mI.) 0·8 ± 0·2 NS 0·8 ± 0·1 0·8 ± 0·2 NS 0·8 ± 0·2 0·8 ± 0·2
Beta-globulin % \2·3 ± 2·2 NS 11·6 ± 2·3 11·8 ± 2·0 NS 12·3 ± 1·7 12·6 ± 3·1
Beta-globulin (G/lOO mI.) 1·0 ± 0·2 NS 0·9 ± 0·2 1·0± 0·2 NS \·0 ± 0·2 1·0 ± 0·3
Gammaglobulin % 32·6 ± 7·0 NS 32·3 ± 8'7 33·7 ± 7·1 NS 31·0 ± 5·8 32·5 ± 6·7
Gammaglobulin (G/lOO mI.) 2·7 ± 0·9 NS 2·6 ± 0·8 2·8 ± 0·8 PS 2·5 ± 0·7 2·7 ± 0·6
Mucoprotein (mg./IOO mI.) 178·0 ± 69·3 NS 177·7 ± 95'4 172·1 ± 67·6 NS \86·9 ± 67·\ 182'2 ± 82·5
C-reactive protein 2·5 ± 1·4 HS 1·2 ± 1·5 2·6 ± I· 3 NS 2·3 ± 1·6 2·1 ± 1·5
TABLE VD. MEANS, STANDARD DEVIATIONS AND STATISTICAL A ALYSES (BILIRUBIN AND CHOLESTEROL)
Proved cancer Non-cancer Cirrhosis No cirrhosis Focal cirrhosis
(93 cases) 'p' (61 cases) (48 cases) 'p' (30 cases) (/2 cases)
Total bilirubin (mg./l00 mI.) 2·5 ± 4·3 NS 1·9 ± 4·3 2·3 ± 2·8 NS 3·3 ± 6·6 1·6 ± 0·9
Cholesterol (mg./IOO mI.) 170·0 ± 74·5 HS 132·7 ± 67·5 160·5 ± 71·5 NS 172·2 ± 73·5 173·\ ± 68·8
Esterified cholesterol % 53·2 ± 15·4 HS 60·7 ± 11·7 52·3 ± 15·3 NS 53·2 ± 16·6 53·8±1\·6
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TABLE VIB. PERCENTAGE OF ABNORMAL TESTS (E ZYMES)
Proved cancer 'on-cancer Cirrhosis '0 cirrhosis Focal cirrhosis
(93 cases) (61 cases) (48 cases) (30 cases) (12 cases)
88 49 85 90 91
97 69 96 100 100
73 57 71 73 75
89 43 89 83 91
97 62 98 100 100
95 65 98 100 100
58 41 60 60 67
95 97 96 97 100
90 65 89 87 100
84 21 79 90 91
75 39 66 83 91
87 52 79 93 100
95 61 91 100 100
89 75 87 87 100
TABLE VIC. PERCE TAGE OF AB 'ORMAL TESTS (PROTEINS)
Proved cancer Non-cancer Cirrhosis No cirrhosis Focal cirrhos~
(93 cases) (61 cases) (48 cases) (30 cases) (/2 cases)
51 56 56 43 58
98 82 98 93 100
58 39 63 53 50
72 36 68 73 75
43 21 48 36 41
32 28 23 40 41
16 18 13 23 9
6 3 4 0 16
18 8 10 14 50
63 52 63 . 57 75
73 64 77 70 67
76 63 75 84 75
91 52 96 80 83
75 8t 81 53 100
82 89 70 100
TABLE VID. PERCENTAGE OF ABNORMAL TESTS (BILlRUBI A D CHOLESTEROL)
occupying lesions of the liver.9 This observation is simi-
lar to that of Jose et al." who stated that elevated levels
of alkaline phophatase, which continued to mount during
the period of observation, were valuable clues to the diag-
nosis of space-occupying lesions of the liver in the ab-
sence of bone disease or jaundice.
The significant increase in the SGOT level in the
cancer group, without significant differences in the
SGPT level, is reflected by a significantly higher SGOT /
SGPT ratio in the cancer group. SGOT has cytoplasmic
and mitochondrial components, while the SGPT is wholly
cytoplasmic. Severe liver cell damage is necessary for
the mitochondrial enzyme to pass into the serum, and
for this reason the ratio in the cancer group was probably
higher than in the non-cancer group....
Isocitric dehydrogenase was significantly elevated in
the cancer group. Elevated levels usually occur during the
early stages of infective hepatitis, and normal levels are
encountered in most cases of obstructive jaundice irre-
spective of causation.'" Raised levels occurred, according
to Okumura and Spellberg," in some patients with he-



















































Total protein above 8·0 G/loo ml.
Albumin below 50%
Albumin below 3·2 G/loo ml.
Alphacglobulin above 5%
Alpha,-globulin above 0·4 G/loo ml.
Alpha.-globulin above 11 %
Alpha.-globulin above 0·96 G/loo ml.
Beta-globulin above 16% ..
Beta-globulin above I .2 G/I 00 ml.
Gammaglobulin above 30 %
Gammaglobulin above 2·2 G/loo ml.
Mucoprotein above 150 mg./loo ml.

















Cholinesterase % of normal
genase, LDH isoenzyme fraction V (liver fraction), aldo-
lase, isocitric dehydrogenase, leucine amino-peptidase,
5'nucleotidase and glutathione reductase were all signifi-
cantly higher (p = <0'01) in the cancer cases. The mean
SGPT and cholinesterase levels were not as significantly
different (although an increased percentage showed ab-
normalities) as was the lactic dehydrogenase/ alpha-
hydroxybutyric dehydrogenase ratio. This was in keeping
with the observation of Elliott and Wilkinson, who found
high ratios of lactic dehydrogenase/alpha-hydroxybutyric
dehydrogenase in acute liver disease, but normal ratios in
chronic liver conditions....
The mean alkaline phosphatase level was only slightly
higher in the cancer group (possibly significant), although
a higher percentage of cases showed raised levels (88 0 0
vs. 49%). In the cancer group 54% were non-icteric (84 0 0
of whom had a raised alkaline phosphatase level), while
in the non-cancer group 81 0 " were non-icteric (49 0 0 of
whom had a raised alkaline phosphatase level). This con-
firms a previous report by one of us (1.8.) that a raised
alkaline phosphatase level in the absence of jaundice is a
useful aid in the diagnosis of malignancy and space-
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with small metastases. Patients with cirrhosi had normal
or only lightly elevated levels. The degree of serum ele-
vation seemed to depend on the ize of the metastatic tu-
mour. Sterkel et al." studied isocitric dehydrogena e
levels in 49 patients with extensive malignancy. Approxi-
mately one-half of the 21 patients with liver metastases
exhibited relatively small elevations of isocitric dehydro-
genase. In the group of 28 cases without liver metastases.
no abnormal levels were noted.
The mean aldolase level was significantly higher in the
cancer group. and 90% of the cancer group had raised
levels. Serum aldolase levels are markedly increased in
the early stages of acute hepatitis. but in other liver
diseases. including cirrhosis and ob tructive jaundice. the
serum aldolase level is usually within normal limits or
only slightly elevated.'" Sibley and Lehninger'"' found
raised levels in 20"" of 104 cancer patients. There was
no correlation with clinical findings. The presence of
actively regenerating liver did not cause increased aldo-
lase levels. Surgical removal of the tumours caused a
prompt decline of the serum aldolase to normal levels.
Warburg and Christian.'''' on the other hand. found no
ignificant increase over normal values in serum of
patients with cancer. They concluded that serum aldolase
level were not of diagnostic usefulnes in human cancer.
Blo tein and Rutter have shown that two types of aldo-
lases occurred in mammalian tissue-aldolase A. which
was specific for fructose-I. 6-diphosphate (FOP). and
aldolase B. which reacted equally with FOP and fruc-
tose-i-phosphate (F IP). Foetal liver contains both aldo-
Iases, and hence shows an FOP / F IP activity ratio of 5,
compared with a ratio of I in the adult. Liver cancer
ti sues have been shown to revert to the foetal condition.
giving ratios of 2·2 - 13,0."""
One of u (LB.) studied the sera of 1I normal sub-
ject who exhibited activities with FOP of 2·1 ± 0·8
units. FIP 0·7 ± 0·4 units. and FOP / FlP ratios of 3·5 ±
1·8. The era of 7 subjects suffering from liver cancer
ga e activities with FOP of 8·7 ± 4·5 units. with FIP
2·3 ± 1·2 units. and FOP/FIP ratios of 4·9 ± 4·2. The
differences between these ratio were not significant.
hence it was felt that the technique could not be used as
a diagnostic test for liver cancer. The mean FOP aldolase
activity of cancerou cases was, however, significantly
raised (p<0·005). FOP aldolase activities were also
mea ured on a larger eries of specimens. Activities of
3·1 ± 0,9, 5·7 ± 3·3 and 3·0 ± I·' units were obtained
for 42 norma Is. 40 cancer case and 27 miscellaneous non-
cancer liver disea e re pectively. The difference between
the mean non-cancer arid cancer values was highly signi-
ficant (p<O·OOI). This was a retrospective tudy and the
40 cancer cases studied were from patients in this tudy:'
The thymol and zinc sulphate turbidity tests were sig-
nificantly higher in the cancer group.
The mean bilirubin levels were only lightly raised in
the two groups. and there was no significant difference.
However. 5400 of the cancer group and 81°,; of the non-
cancer group were anicteric. emphasizing that marked
bilirubinaemia is not a prominent feature of malignant
hepatoma.
The cholesterol level wa ignificantly higher in the
cancer group ami the percentage of e. terified to total
chole terol wa ignificantly lower. We have previously
mentioned that a high cholesterol level favours a diag-
nosis of primary cancer of the liver, but since the range
of levels is very wide, no importance can be attached to
individual results:
Apart from a significantly increased level of the alpha.-
globulin, there were no significant differences in the
total protein, albumin, alpha,-, beta- and gammaglobulin
level.
A higher percentage of low albumin levels (below 3·2
G/ 100 ml.) was found in the cancer group (58°0 \·5. 39°0).
The cancer group had a raised alpha.-globulin level (43°0
\·5. 21 °0 ) compared with the non-cancer group.
A higher percentage of cases in the cancer group had
raised beta-globulin levels than in the non-cancer group
(18 \·5. 8), while there was little difference in the percen-
tage of cases showing raised gammaglobulin levels in the
two groups (73 1"5. 64).
The C-reactive protein was statistically higher in the
malignant group and there was a higher percentage of
abnormal results (91 o~ vs. 52°0).
There was no significant difference in the mean serum
mucoprotein level. This was in contrast to our previous
study that compared mucoprotein levels in primary
cancer of the liver with portal cirrhosis of the liver in
the Bantu. There was a significant difference in these two
groups. In the present series we compared cases of pri-
mary cancer of the liver with a heterogenous group of
cases with a similar clinical presentation to primary liver
cancer, and bearing in mind that some of the non-cancer
group had 'space-occupying lesions' of the liver, and in-
fections, it is not surprising that the mucoprotein levels
were similar in the two groups.
When the cases with cirrho is and without cirrhosis
were compared (those with histological evidence of focal
cirrhosis were omitted) there were possibly significant dif-
ferences in the SGPT level, and highly significant differences
in the SGOT/ SG PT ratio and in the leucine amino-
peptidase levels. The only significant difference in the pro-
tein pattern was a slightly increased gammaglobulin level
in the cirrhotic group. The thymol flocculation, colloidal
red, the Takata Ara reaction and the zinc sulphate tur-
bidity tests were all significantly increased in the cirrhotic
group.
The bilirubin. cholesterol (total and esterified) and alka-
line phosphatase levels were not significantly different in
the two groups.
The cases have also been subdivided according to the
presence of pulmonary metastases on admission. later
proved at po tmortem examination (23 case), or as to
whether metastases were not present at postmortem (41
cases). The only significant differences between these two
group were increases in the LOH, alpha-hydroxybutyric
dehydrogenase and total protein in the metastatic group.
The AFP (quantitative)'" test was positive initially in
75·2°0 and eventually in 82°6 of the cancer group. This
agrees with our positivity rate of 76°0 in a larger series.
There were 5 ca e~ in the 'non-proved' group with a posi-
tive AFP test but in whom no final diagnosis was made.
These cases were lost to follow-up as the A FP test was
strictly retro pective, and these cases may well ha e had
primary cancer of the liver.
A detailed analy is of the relationship between all the
biochemical parameters and the pre ence or the concen-
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tration of AFP revealed no striking correlations. This was
not altogether surprising, as none of the biochemical tests
was of such definite discriminatory value as the AFP test.
However, by dividing our cases into groups (alpha-
teto-protein-absent, less than 20 mg./IOO m!. and more
than 20 mg. /100 m!.), we were able to establish definite
gradients.'" The mucoprotein, C-reactive protein and
alpha,-globulin decreased (each with a ignificance level
of at least p<0'05) as the AFP rose. Serum cholesterol
and total protein increased. Scrutiny of the data did not
enable us to attribute this gradient to a greater degree of
liver damage or cirrhosis in the AFP-positive group. The
usual biochemical indicators of cirrhosis, even in the
presence of primary cancer of the liver (Tables VA - VD),
were observed when the cirrhotic and non-cirrhotic
groups were compared. This was not the case with the
three AFP groups, although there is a suggestion that
initially the non-cirrhotic group had fewer AFP-positive
cases (53°~ \·s. 70'l~) although the absolute mean value of
AFP was not different.
Eventual survival time (from the date of the first ymp-
tom) was compared with all our parameters on admission.
The cases were grouped: 30, 60, 90, 120, <200, >200
days. In the first three groups there was a significant
gradient for zinc sulphate turbidity, SGOT and SGPT,
which were higher in the shorter survivals, otherwise the
results were similar for the rest of the groups. There was
a possibly significant gradient for all the groups for
gammaglobulin, the value being higher in short survivals.
It appears that there are no biochemical tests that can
be considered specific enough to be diagnostic of primary
cancer of the liver. A combination of tests such as
markedly elevated enzyme levels, a raised cholesterol
level, a dissociation between the alkaline phosphatase and
bilirubin level (particularly a raised alkaline phosphatase
level in the absence of jaundice), may be used as possible
presumptive evidence of primary liver cancer. The only
test that affords a specific diagnosis of primary cancer of
the liver, in approximately 82'l~ of cases, is the AFP test.
AFP has not been found in the sera of several
thousand healthy individuals tested nor in patients with
a wide variety of cancers other than hepatocellular carci-
noma (except for positive results in a few cases of neo-
plasms of embryonal character) even when the liver con-
tained metastases.'"
SUMMARY
A wide range of biochemical liver-function tests were carried
out on an unbroken series of Bantu mineworker of the Wit-
waters rand and Orange Free State goldrnines suspected of
having primary cancer of the liver. There were 93 cases, proved
at postmortem examination, of primary cancer of the liver.
These cases were further categorized into cirrhotic, focal cir-
rhotic and non-cirrhotic groups.
There were 61 cases which were negative for cancer by re-
peated liver biopsies. The biochemical liver-function tests of
these groups were compared. 0 single biochemical test was
considered specific enough to be diagnostic of primary cancer
of the liver, but a combination of tests could be used as possible
presumptive evidence.
The only test that affords a specific diagnosis of cancer of
the liver is the alpha-feto-protein test which is positive in
approximately 82% of cases.
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